Materias dentro de su búsqueda.
Mostrando 4,661 - 4,680 Resultados de 4,918 Para Buscar '"Pfizer"', tiempo de consulta: 0.81s Limitar resultados
  1. 4661
    “…A primeira vacina utilizada foi a Coronavac (Sinovac/Butantan), sendo posteriormente incluídas as vacinas Covishield (Astra-zeneca/Fiocruz), mRNA contra COVID-19 da Pfizer e recentemente a Janssen. Até 31/03/2022 foram aplicadas pelo CECOM, 22.357 doses, das quais 6.285 correspondem à primeira dose, 6.198 segunda dose, 9.868 primeira dose adicional e 6 segunda dose adicional. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    PLANEJAMENTO E OPERACIONALIZAÇÃO DA CAMPANHA DE IMUNIZAÇÃO CONTRA A COVID-19 REALIZADOS PARA A COMUNIDADE INTERNA DA UNIVERSIDADE ESTADUAL DE CAMPINAS (UNICAMP) PELO CENTRO DE SAÚDE DA COMUNIDADE (CECOM)
  2. 4662
    “…BACKGROUND: The two-dose BNT162b2 (Pfizer-BioNTech) vaccine has demonstrated high efficacy against COVID-19 disease in clinical trials of children and young people (CYP). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    BNT162b2 COVID-19 vaccination uptake, safety, effectiveness and waning in children and young people aged 12–17 years in Scotland
  3. 4663
    “…The current national guidance recommends that immunocompromised children between 12 and 18 years of age should be offered three primary doses of the Pfizer BioNTech vaccine, 8 weeks apart, followed by a booster dose within 3 months. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    P69 COVID vaccine uptake in young persons on immunosuppression under the care of tertiary paediatric rheumatology service
  4. 4664
    “…Using this expression, together with the baseline values of the parameters of the parameterized model, we showed that the vaccine-derived herd immunity can be achieved in the United States (so that the pandemic will be eliminated) if at least [Formula: see text] of the population is fully-vaccinated with two of the three vaccines approved for use in the United States (Pfizer or Moderna vaccine). Furthermore, this study showed (as of the time of writing in March 2022) that the control reproduction number of the Omicron variant was approximately 3.5 times that of the Delta variant (the reproduction of the latter is computed to be [Formula: see text]), indicating that Delta had practically died out and that Omicron has competitively-excluded Delta (to become the predominant variant in the United States). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Unraveling the dynamics of the Omicron and Delta variants of the 2019 coronavirus in the presence of vaccination, mask usage, and antiviral treatment
  5. 4665
    “…In January 2021, he received 2 doses of the mRNA BNT162b2-SARS-CoV-2 vaccine (Pfizer-BioNTech). Three weeks after the second dose, TED deteriorated significantly with severe eye pain, lid swelling, conjunctival erythema, and worsening proptosis and diplopia (CAS 6/7). …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    RF35 | PSAT299 Thyroid Eye Disease Activation After mRNA SARS-CoV-2 Vaccination in Patients With Autoimmune Thyroid Disease
  6. 4666
    “…Geometric mean IgG levels were higher after vaccination with the mRNA-1273 (Moderna) vaccine compared with the BNT162b2 (Pfizer/BioNTech) vaccine (53.74 [95% CI, 40.49-71.33] arbitrary U/mL vs 25.45 [95% CI, 19.17-33.79] arbitrary U/mL; P < .001). …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Comparison of Maternal and Neonatal Antibody Levels After COVID-19 Vaccination vs SARS-CoV-2 Infection
  7. 4667
    “…A total of 2 039 854 individuals who received any dose of a COVID-19 vaccine with emergency use authorization (BNT162b2 [Pfizer-BioNTech], mRNA-1273 [Moderna], or Ad26.COV2.S [Johnson & Johnson]) from December 11, 2020, through June 30, 2021, were eligible for inclusion. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Assessment of Herpes Zoster Risk Among Recipients of COVID-19 Vaccine
  8. 4668
    “…Elle reçut une première dose du vaccin anti-SARS-CoV-2 Pfizer BioNtech Comirnaty® en avril 2021 bien tolérée, suivie de la deuxième injection en juin 2021. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Érythème pigmenté fixe bulleux généralisé post-vaccination anti-SARS-CoV-2
  9. 4669
    “…Here we report the results of a survey of 4825 individuals from southcentral Kentucky who received two doses of either the Pfizer-BioNTech (BNT162b2) or Moderna (mRNA-1273) vaccine between December 14, 2020 and May 1, 2021. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    From trial to practice: incidence and severity of COVID-19 vaccine side effects in a medically at-risk and vaccine-hesitant community
  10. 4670
    “…Hammond, MD, F2G: Advisor/Consultant|F2G: Grant/Research Support|GSK: Grant/Research Support|Merck: Grant/Research Support|pfizer: Advisor/Consultant|Scynexis: Grant/Research Support Nicolas C. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    733. Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study.
  11. 4671
    “…Smith, M.D., M.S.C.E, Merck: Grant/Research Support|Pfizer: Grant/Research Support.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    961. Pandemic Hits: Evaluation of an Antimicrobial Stewardship Program Website for Hospital Communication During the COVID-19 Pandemic
  12. 4672
    “…Greninger, MD, PhD, Abbott: Contract Testing|Cepheid: Contract Testing|Gilead: Grant/Research Support|Gilead: Contract Testing|Hologic: Contract Testing|Merck: Grant/Research Support|Novavax: Contract Testing|Pfizer: Contract Testing Jiani Li, PhD, Gilead Sciences: Stocks/Bonds Jason Perry, PhD, Gilead Sciences: Employee|Gilead Sciences: Stocks/Bonds Dong Han, MS, Gilead Sciences: Stocks/Bonds Gregory Camus, PhD, Gilead Sciences: Employee and shareholder|Gilead Sciences: Stocks/Bonds Danielle P. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1149. Resistance Analyses of Patient Viral Samples from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)
  13. 4673
    “…Lee, PhD, MPH, CDC: Grant/Research Support|Merck: Grant/Research Support Christopher J Harrison, MD, Astellas: Grant/Research Support|GSK: Grant/Research Support|Merck: Grant/Research Support|Pediatric news: Honoraria|Pfizer: Grant/Research Support Mary E. Moffatt, M.D., Becton and Dickinson and Company: Stocks/Bonds|Biogen: Stocks/Bonds|Coloplast B: Stocks/Bonds|Express Scripts: Stocks/Bonds|Novo Nordisk A/S Spons ADR: Stocks/Bonds|Novo Nordisk A/S-B: Stocks/Bonds|Steris PLC: Stocks/Bonds|Stryker Corp: Stocks/Bonds|Thermo Fisher Scientific: Stocks/Bonds Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, F(AAM), BioFire: Grant/Research Support|Luminex: Grant/Research Support.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1459. Prevalence of Enterovirus and Parechovirus in Children with Acute Gastroenteritis and in Healthy Controls over a 7-year Period; 2011-2018
  14. 4674
    “…Hill, MD, Allovir: Advisor/Consultant|Allovir: Grant/Research Support|Covance/CSL: Advisor/Consultant|CRISPR: Advisor/Consultant|Deverra: Grant/Research Support|Gilead: Grant/Research Support|Karius: Advisor/Consultant|Karius: Grant/Research Support|Merck: Grant/Research Support|Octapharma: Advisor/Consultant|OptumHealth: Advisor/Consultant|Oxford Immunotec: Grant/Research Support|Pfizer: Advisor/Consultant|Symbio: Advisor/Consultant|Takeda: Advisor/Consultant.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2109. HHV-6 and EBV Reactivation after Allogeneic Hematopoietic Cell Transplantation in the Era of Letermovir for CMV Prophylaxis: A Retrospective Cohort Study
  15. 4675
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Real-World Study of Regional Differences in Patient Demographics, Clinical Characteristics, and BRCA1/2 Mutation Testing in Patients with Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer in the United States, Europe, and Israel
  16. 4676
    “…BACKGROUND: The effectiveness of the second BNT162b2 (Pfizer–BioNTech) mRNA COVID-19 booster vaccine dose (ie, fourth inoculation) is well established, but its safety has yet to be fully understood. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Safety of the fourth COVID-19 BNT162b2 mRNA (second booster) vaccine: a prospective and retrospective cohort study
  17. 4677
    “…OBJECTIVE: To evaluate GBS reports to the Vaccine Adverse Event Reporting System (VAERS) and compare reporting patterns within 21 and 42 days after vaccination with Ad26.COV2.S (Janssen), BNT162b2 (Pfizer-BioNTech), and mRNA-1273 (Moderna) COVID-19 vaccines. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Reports of Guillain-Barré Syndrome After COVID-19 Vaccination in the United States
  18. 4678
    “…Nursing/midwifery (39.3%, n = 922) was the most common job role. 97.7% of participants were fully vaccinated, with Pfizer (81.1%, n = 1,902) and AstraZeneca (16.1%, n = 377) the most common vaccines received. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    SARS-CoV-2 epidemiology, antibody dynamics, and neutralisation capacity in Irish healthcare workers in the era of booster COVID-19 vaccinations
  19. 4679
    por Moore, Shona C., Kronsteiner, Barbara, Longet, Stephanie, Adele, Sandra, Deeks, Alexandra S., Liu, Chang, Dejnirattisai, Wanwisa, Reyes, Laura Silva, Meardon, Naomi, Faustini, Sian, Al-Taei, Saly, Tipton, Tom, Hering, Luisa M., Angyal, Adrienn, Brown, Rebecca, Nicols, Alexander R., Dobson, Susan L., Supasa, Piyada, Tuekprakhon, Aekkachai, Cross, Andrew, Tyerman, Jessica K., Hornsby, Hailey, Grouneva, Irina, Plowright, Megan, Zhang, Peijun, Newman, Thomas A.H., Nell, Jeremy M., Abraham, Priyanka, Ali, Mohammad, Malone, Tom, Neale, Isabel, Phillips, Eloise, Wilson, Joseph D., Murray, Sam M., Zewdie, Martha, Shields, Adrian, Horner, Emily C., Booth, Lucy H., Stafford, Lizzie, Bibi, Sagida, Wootton, Daniel G., Mentzer, Alexander J., Conlon, Christopher P., Jeffery, Katie, Matthews, Philippa C., Pollard, Andrew J., Brown, Anthony, Rowland-Jones, Sarah L., Mongkolsapaya, Juthathip, Payne, Rebecca P., Dold, Christina, Lambe, Teresa, Thaventhiran, James E.D., Screaton, Gavin, Barnes, Eleanor, Hopkins, Susan, Hall, Victoria, Duncan, Christopher J.A., Richter, Alex, Carroll, Miles, de Silva, Thushan I., Klenerman, Paul, Dunachie, Susanna, Turtle, Lance
    Publicado 2023
    “…In a large prospective study of UK healthcare workers (HCWs) (Protective Immunity from T Cells in Healthcare Workers [PITCH], within the larger SARS-CoV-2 Immunity and Reinfection Evaluation [SIREN] study), we previously observed that prior infection strongly affected subsequent cellular and humoral immunity induced after long and short dosing intervals of BNT162b2 (Pfizer/BioNTech) vaccination. METHODS: Here, we report longer follow-up of 684 HCWs in this cohort over 6–9 months following two doses of BNT162b2 or AZD1222 (Oxford/AstraZeneca) vaccination and up to 6 months following a subsequent mRNA booster vaccination. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evolution of long-term vaccine-induced and hybrid immunity in healthcare workers after different COVID-19 vaccine regimens
  20. 4680
    “…(Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04816643.)…”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age
Herramientas de búsqueda: RSS